Beijing Kontine Pharmaceutical

Beijing Kontine Pharmaceutical is a China-based pharmaceutical company specializing in the development and commercialization of therapies for organ fibrosis. The company's lead candidate, F351 (Hydronidone), is a small molecule inhibitor of TGF-beta signaling currently in Phase 3 clinical trials for the treatment of chronic hepatitis B-associated liver fibrosis. Kontine also markets Etuary (Pirfenidone) in China, which was the first approved treatment for idiopathic pulmonary fibrosis in the country. As a key subsidiary of the GNI Group, the company leverages its research and manufacturing capabilities to address significant unmet needs in fibrotic diseases of the liver, lungs, and kidneys.